fbpx
 

December 3, 2013

Aratana Therapeutics, a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, entered into a merger agreement providing for the strategic acquisition of Vet Therapeutics, Inc., a San Diego-based company with a proprietary antibody-based biologics platform.

Under the agreement, Aratana plans to continue to advance the pipeline of high value biologic drugs, including its lymphoma franchise. Lymphoma is the most common blood cancer in dogs, accounting for an estimated 6 percent of total dog cancers, the company said.

The acquisition of Vet Therapeutics is expected to significantly accelerate Aratana’s pathway toward becoming a commercial-stage pet therapeutics company.

Share This Story On:

Stockroom //
New Products


Digital Guide

CBD Trends

This digital guide provides valuable information on the subject of CBD, including content on dosage and the importance of being fully transparent about the product’s origin

Dog & Cat Needs

With dogs and cats being members of the family, there's vital information to know in order to serve their pet parents.

Pet Health

This digital guide describes a variety of health issues and the ways that pet parents can care for their pet's well-being through pet supplements..

Pet Nutrition

Discover how science, technology and pet owning lifestyles are changing the industry.

Pet Parenting

This digital guide dives into the human-animal bond, and the roles that pet parents play in the development of their companion animals.

Pet Supplements

This digital guide provides valuable information on the subject of pet supplements, including details on the NASC and how brands should earn consumer trust.

Enews Subscribe


6226
close
Subscribe To Pet Age
Sign up for the weekly e-newsletter, print magazine and more. Sign Up